Restore Medical has announced preliminary results of the first-in-human clinical trial of ContraBand, a breakthrough treatment for patients suffering from congestive heart failure. The minimally-invasive, catheter-delivered implants are used to treat patients with chronic left ventricular failure.
ContraBand has been implanted in its first patients at the ZNA Medical Center, Antwerp, Belgium, followed by Kaplan Medical Center, Rehovot, Israel.
“These first procedures are milestones in proving the ContraBand technology to be both safe and effective for heart failure patients,” said Gilad Marom, CEO of Restore Medical. “The positive impact this treatment can have on the millions of people suffering from congestive heart failure cannot be underestimated. Not only will it transform the quality of life of treated patients, but it will also reduce the enormous financial burden that comes as a result of patients being undertreated.”
The ContraBand is expected to relieve symptoms and improve patients’ quality of life by causing the healthy right ventricle to assist the failing left ventricle.
